It would be a concern if MDI was not a growth stock with $23Million in the bank.
Lots of country approvals for Green Whistle, with many hospitals and ambulance services becoming new customers with sales building over time. Several partner organisations who have committed to milestone payments. New markets to conquer (USA) and new technology (CF) currently used in a limited way to produce Methoxyflurane. We are waiting for the company to tell us how CF can be commercialised further.
MVP Price at posting:
$7.60 Sentiment: Hold Disclosure: Held
